| Schedule of Segment Revenue, Segment Profit and Segment Expenses |
The following table illustrates reported segment revenue, segment profit and significant segment expenses (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
NUPLAZID net revenue |
|
$ |
183,132 |
|
|
$ |
168,479 |
|
|
$ |
350,056 |
|
|
$ |
328,199 |
|
DAYBUE products net revenue |
|
|
124,827 |
|
|
|
96,087 |
|
|
|
225,965 |
|
|
|
180,683 |
|
Total revenues |
|
|
307,959 |
|
|
|
264,566 |
|
|
|
576,021 |
|
|
|
508,882 |
|
Less: |
|
|
|
|
|
|
|
|
|
|
|
|
Cost of product sales |
|
|
12,785 |
|
|
|
8,384 |
|
|
|
24,449 |
|
|
|
17,595 |
|
License fees and royalties |
|
|
15,531 |
|
|
|
12,350 |
|
|
|
28,658 |
|
|
|
23,531 |
|
Research and development expense: |
|
|
|
|
|
|
|
|
|
|
|
|
External research and development |
|
|
55,395 |
|
|
|
54,319 |
|
|
|
104,218 |
|
|
|
109,304 |
|
Internal costs(1) |
|
|
26,160 |
|
|
|
23,632 |
|
|
|
51,704 |
|
|
|
46,912 |
|
Upfront and milestone payments |
|
|
— |
|
|
|
— |
|
|
|
2,501 |
|
|
|
— |
|
Total research and development expense |
|
|
81,555 |
|
|
|
77,951 |
|
|
|
158,423 |
|
|
|
156,216 |
|
Selling, general and administrative |
|
|
160,252 |
|
|
|
133,507 |
|
|
|
331,271 |
|
|
|
259,877 |
|
Interest income, net |
|
|
(7,990 |
) |
|
|
(7,243 |
) |
|
|
(16,045 |
) |
|
|
(15,144 |
) |
Other income |
|
|
(647 |
) |
|
|
(594 |
) |
|
|
(1,189 |
) |
|
|
(1,183 |
) |
Income tax expense |
|
|
14,973 |
|
|
|
13,545 |
|
|
|
15,317 |
|
|
|
22,337 |
|
Consolidated net income |
|
$ |
31,500 |
|
|
$ |
26,666 |
|
|
$ |
35,137 |
|
|
$ |
45,653 |
|
_______________ (1)Includes personnel expenses and costs allocated to multiple research and development programs, including benefits, information technology, facilities and inventory.
|